NCT04871607View on ClinicalTrials.gov

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

October 2, 2027

Study Completion Date

October 2, 2027

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
BIOLOGICAL

Basiliximab

Given IV

DRUG

Carmustine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Genetically Engineered Hematopoietic Stem Progenitor Cells

Given via infusion

BIOLOGICAL

Recombinant Granulocyte Colony-Stimulating Factor

Given SC or IV

BIOLOGICAL

Yttrium Y 90 Basiliximab

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER